Online inquiry

IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13914MR)

This product GTTS-WQ13914MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets INHBA gene. The antibody can be applied in Fibrodysplasia ossificans prograssiva (FOP) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002192.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3624
UniProt ID P08476
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13914MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3758MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ7516MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GC-1102
GTTS-WQ4126MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BI-505
GTTS-WQ692MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA A-1230717
GTTS-WQ15314MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ2080MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ6939MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ENIA11
GTTS-WQ2921MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG888
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW